Is it Time to Dump LogicBio Therapeutics Inc (LOGC) Stock After it Is Up 614.29% in a Week?

Tuesday, October 04, 2022 11:49 AM | InvestorsObserver Analysts

Mentioned in this article

Is it Time to Dump LogicBio Therapeutics Inc (LOGC) Stock After it Is Up 614.29% in a Week?

Overall market sentiment has been high on LogicBio Therapeutics Inc (LOGC) stock lately. LOGC receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

LogicBio Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on LOGC!

See Full LOGC Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With LOGC Stock Today?

LogicBio Therapeutics Inc (LOGC) stock is lower by -0.42% while the S&P 500 is up 2.77% as of 11:48 AM on Tuesday, Oct 4. LOGC has fallen -$0.01 from the previous closing price of $2.01 on volume of 1,900,004 shares. Over the past year the S&P 500 is lower by -12.10% while LOGC has fallen -54.75%. LOGC lost -$0.16 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for LogicBio Therapeutics Inc click here.

More About LogicBio Therapeutics Inc

LogicBio Therapeutics Inc is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, its proprietary technology platform. Its product candidates include LB-001, LB-101, LB-201 and LB 301. Click Here to get the full Stock Report for LogicBio Therapeutics Inc stock.